Treatment with lopinavir–ritonavir did not add value beyond standard care in severely ill patients hospitalized with novel coronavirus disease (COVID-19). Findings from the open-label, randomized trial appear in the New England Journal of Medicine.
Roughly 200 adults in China hospitalized with COVID-19 and oxygen saturation of 94% or lower were assigned to lopinavir–ritonavir twice daily for 14 days plus standard care, or standard care alone. The primary outcome — time to clinical improvement — did not differ between the groups (median, 16 days). Mortality at 28 days was numerically lower with lopinavir–ritonavir, but the between-groups difference did not reach statistical significance (19% with lopinavir–ritonavir, 25% with standard care alone).
original article: jwatch